Market Closed -
Nasdaq
04:00:00 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
10.28
USD
|
+1.08%
|
|
-3.11%
|
-27.55%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
2,482
|
6,017
|
3,218
|
3,430
|
4,161
|
3,045
|
-
|
-
|
Enterprise Value (EV)
1 |
2,179
|
5,923
|
3,125
|
3,529
|
4,263
|
3,184
|
3,069
|
2,517
|
P/E ratio
|
-6.58
x
|
-21.6
x
|
-12.6
x
|
-14.9
x
|
-27.8
x
|
-1,694
x
|
26.5
x
|
10.3
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
13.6
x
|
23.1
x
|
10.5
x
|
10.4
x
|
10.4
x
|
5.76
x
|
4.47
x
|
3.34
x
|
EV / Revenue
|
12
x
|
22.7
x
|
10.2
x
|
10.7
x
|
10.7
x
|
6.02
x
|
4.51
x
|
2.76
x
|
EV / EBITDA
|
-7.28
x
|
-24.9
x
|
-15.6
x
|
-17.1
x
|
-61.5
x
|
67
x
|
14.1
x
|
6.49
x
|
EV / FCF
|
-8.06
x
|
-25
x
|
-15.1
x
|
-20.7
x
|
-55.7
x
|
20.9
x
|
13.2
x
|
8.44
x
|
FCF Yield
|
-12.4%
|
-3.99%
|
-6.6%
|
-4.83%
|
-1.8%
|
4.79%
|
7.57%
|
11.8%
|
Price to Book
|
5.22
x
|
21.1
x
|
10.5
x
|
27.9
x
|
26.1
x
|
9.27
x
|
5.03
x
|
3.31
x
|
Nbr of stocks (in thousands)
|
254,810
|
260,588
|
278,646
|
280,945
|
293,257
|
296,176
|
-
|
-
|
Reference price
2 |
9.740
|
23.09
|
11.55
|
12.21
|
14.19
|
10.28
|
10.28
|
10.28
|
Announcement Date
|
3/2/20
|
3/1/21
|
2/24/22
|
3/1/23
|
2/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
182.2
|
260.9
|
305.5
|
329.2
|
399.4
|
529
|
680.8
|
911.2
|
EBITDA
1 |
-299.3
|
-238.2
|
-200.2
|
-206.8
|
-69.34
|
47.54
|
217.8
|
388
|
EBIT
1 |
-304
|
-247
|
-206.4
|
-212.1
|
-77.21
|
40.07
|
161.5
|
347
|
Operating Margin
|
-166.84%
|
-94.68%
|
-67.57%
|
-64.43%
|
-19.33%
|
7.58%
|
23.72%
|
38.08%
|
Earnings before Tax (EBT)
1 |
-355.9
|
-274.3
|
-241.6
|
-242
|
-150.1
|
-3.009
|
126.4
|
317.2
|
Net income
1 |
-356.4
|
-276.9
|
-250.5
|
-236.6
|
-151.6
|
-1.477
|
120.1
|
262.3
|
Net margin
|
-195.56%
|
-106.12%
|
-81.98%
|
-71.85%
|
-37.96%
|
-0.28%
|
17.63%
|
28.78%
|
EPS
2 |
-1.480
|
-1.070
|
-0.9200
|
-0.8200
|
-0.5100
|
-0.006070
|
0.3876
|
0.9946
|
Free Cash Flow
1 |
-270.4
|
-236.5
|
-206.4
|
-170.3
|
-76.53
|
152.5
|
232.5
|
298.2
|
FCF margin
|
-148.39%
|
-90.66%
|
-67.55%
|
-51.74%
|
-19.16%
|
28.83%
|
34.14%
|
32.73%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
320.75%
|
106.73%
|
76.85%
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
193.62%
|
113.71%
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/2/20
|
3/1/21
|
2/24/22
|
3/1/23
|
2/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
79.54
|
82.15
|
78.72
|
80.73
|
81.69
|
88.1
|
86.27
|
94.5
|
103.5
|
115.1
|
111.2
|
124.9
|
139.1
|
155.5
|
144.7
|
EBITDA
1 |
-40.88
|
-70.63
|
-67.31
|
-59.28
|
-32.55
|
-41.02
|
-36.38
|
-16.65
|
-14.8
|
-1.51
|
-14.35
|
-3.697
|
7.425
|
25.99
|
-
|
EBIT
1 |
-42.4
|
-72.15
|
-75.34
|
-60.61
|
-33.84
|
-42.33
|
-37.64
|
-18.86
|
-17.02
|
-3.692
|
-8.679
|
4.211
|
15.68
|
28.86
|
15.88
|
Operating Margin
|
-53.3%
|
-87.82%
|
-95.71%
|
-75.08%
|
-41.42%
|
-48.05%
|
-43.63%
|
-19.96%
|
-16.45%
|
-3.21%
|
-7.81%
|
3.37%
|
11.28%
|
18.56%
|
10.98%
|
Earnings before Tax (EBT)
1 |
-50.48
|
-80.3
|
-81.45
|
-61.25
|
-29.26
|
-70.08
|
-53.22
|
-40.52
|
-24.7
|
-31.66
|
-18.47
|
-6.056
|
9.094
|
21.9
|
4.713
|
Net income
1 |
-50.29
|
-83.28
|
-85.26
|
-62.16
|
-33.29
|
-55.86
|
-52.93
|
-43.23
|
-21.58
|
-33.84
|
-19.69
|
-7.394
|
7.044
|
20.64
|
4.713
|
Net margin
|
-63.23%
|
-101.37%
|
-108.31%
|
-76.99%
|
-40.75%
|
-63.41%
|
-61.36%
|
-45.75%
|
-20.85%
|
-29.41%
|
-17.71%
|
-5.92%
|
5.06%
|
13.27%
|
3.26%
|
EPS
2 |
-0.1900
|
-0.2900
|
-0.3000
|
-0.2100
|
-0.1200
|
-0.1900
|
-0.1800
|
-0.1500
|
-0.0700
|
-0.1100
|
-0.0644
|
-0.0222
|
0.0189
|
0.0633
|
0.0140
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/9/21
|
2/24/22
|
5/9/22
|
8/4/22
|
11/7/22
|
3/1/23
|
5/10/23
|
8/8/23
|
11/8/23
|
2/28/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
98.4
|
102
|
139
|
24.3
|
-
|
Net Cash position
1 |
303
|
94
|
93.1
|
-
|
-
|
-
|
-
|
527
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-0.4758
x
|
-1.466
x
|
2.924
x
|
0.1116
x
|
-
|
Free Cash Flow
1 |
-270
|
-237
|
-206
|
-170
|
-76.5
|
153
|
232
|
298
|
ROE (net income / shareholders' equity)
|
-87%
|
-72.6%
|
-84.4%
|
-110%
|
-107%
|
-1.44%
|
35.8%
|
36%
|
ROA (Net income/ Total Assets)
|
-43.5%
|
-31.9%
|
-28%
|
-29%
|
-5.13%
|
17%
|
29%
|
-
|
Assets
1 |
820.1
|
868.4
|
895.8
|
814.7
|
2,957
|
-8.671
|
413.5
|
-
|
Book Value Per Share
2 |
1.870
|
1.090
|
1.100
|
0.4400
|
0.5400
|
1.110
|
2.040
|
3.110
|
Cash Flow per Share
2 |
-1.040
|
-0.9000
|
-0.7500
|
-0.5800
|
-0.2300
|
0.1800
|
0.6100
|
-
|
Capex
1 |
20
|
3.23
|
3.88
|
3.77
|
7.44
|
5.22
|
5.13
|
7.18
|
Capex / Sales
|
10.98%
|
1.24%
|
1.27%
|
1.14%
|
1.86%
|
0.99%
|
0.75%
|
0.79%
|
Announcement Date
|
3/2/20
|
3/1/21
|
2/24/22
|
3/1/23
|
2/28/24
|
-
|
-
|
-
|
Last Close Price
10.28
USD Average target price
18.78
USD Spread / Average Target +82.66% Consensus |
1st Jan change
|
Capi.
|
---|
| -27.55% | 3.04B | | +1.51% | 42.75B | | +8.57% | 41.34B | | +49.22% | 41.61B | | -12.36% | 26.59B | | +8.92% | 25.49B | | -25.13% | 18.12B | | +29.17% | 12.24B | | -3.12% | 11.76B | | +6.35% | 11B |
Other Biotechnology & Medical Research
|